Aya Nakaya

Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab

Aya Nakaya, Takayasu Kurata, Hiroshige Yoshioka et al. · International Journal of Clinical Oncology · 2018 · 127 citations · Full text

The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-κB activity

Aya Nakaya, M. Sagawa, Akihiro Muto et al. · Leukemia Research · 2010 · 92 citations

Inflammation, Nf-κb Activity, Anti-inflammatory +10

Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer

Maiko Niki, Aya Nakaya, Takayasu Kurata et al. · Oncotarget · 2018 · 77 citations · Full text

Delayed HBV reactivation in rituximab-containing chemotherapy: How long should we continue anti-virus prophylaxis or monitoring HBV-DNA?

Aya Nakaya, Shinya� Fujita, Atsushi� Satake et al. · Leukemia Research · 2016 · 47 citations

Delayed Hbv Reactivation, Oncology, Rituximab-containing Chemotherapy +8

Does the Hematopoietic Cell Transplantation Specific Comorbidity Index (HCT-CI) Predict Transplantation Outcomes? A Prospective Multicenter Validation Study of the Kanto Study Group for Cell Therapy

Aya Nakaya, Takehiko Mori, Masatsugu Tanaka et al. · Biology of Blood and Marrow Transplantation · 2014 · 45 citations